Targeted knockdown of Bcl2 in tumor cells using a synthetic TRAIL 3'-UTR microRNA

International Journal of Cancer

Volumn 126, Issue 9, 2010, Pages 2229-2239

  Zhang, Jianjun ^a   Huang, Shenglin ^a   Zhang, He ^a,b   Wang, Haibo ^a,b   Guo, Haiyan ^a   Qian, Guanxiang ^a   Fan, Xianqun ^a   Lu, Jian ^a   Hoffman, Andrew R ^b   Hu, Ji Fan ^b   Ge, Shengfang ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bcl2; Synthetic 30 UTR miRNA; Telomerase reverse transcriptase promoter; TRAIL; Tumor gene therapy

Indexed keywords

CASPASE 3; MICRORNA; PROTEIN BCL 2; TELOMERASE REVERSE TRANSCRIPTASE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TNFSF10 PROTEIN, HUMAN;

3' UNTRANSLATED REGION; APOPTOSIS; ARTICLE; CANCER CELL; CANCER GENE THERAPY; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION; GENE SILENCING; GENE TARGETING; HUMAN; HUMAN CELL; KNOCKOUT GENE; MONOTHERAPY; PRIORITY JOURNAL; PROMOTER REGION; RNA INTERFERENCE; SENSITIZATION; DRUG ANTAGONISM; GENETICS; NEOPLASM; TUMOR CELL LINE;

3' UNTRANSLATED REGIONS; APOPTOSIS; CELL LINE, TUMOR; HUMANS; MICRORNAS; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA INTERFERENCE; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 77949896497     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24821     Document Type: Article

References (51)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
2. Yano J, Hirabayashi K, Nakagawa S, Yamaguchi T, Nogawa M, Kashimori I, Naito H, Kitagawa H, Ishiyama K, Ohgi T, Irimura T. Antitumor activity of small interfering RNA/cationic liposome complex in mouse models of cancer. Clin Cancer Res 2004;10:7721-7726
3. Brummelkamp TR, Bernards R, Agami R. Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell 2002;2:243-247
4. Choudhury A, Charo J, Parapuram SK, Hunt RC, Hunt DM, Seliger B, Kiessling R. Small interfering RNA (siRNA) inhibits the expression of the Her2/neu gene, upregulates HLA class I and induces apoptosis of Her2/neu positive tumor cell lines. Int J Cancer 2004;108:71-77
5. Kirkin V, Joos S, Zornig M. The role of Bcl-2 family members in tumorigenesis. Biochim Biophys Acta 2004;1644:229-249
6. Cory S, Adams JM. The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer 2002;2:647-656
7. Reed JC. Bcl-2 family proteins: regulators of apoptosis and chemoresistance in hematologic malignancies. Semin Hematol 1997;34:9-19.
8. Baliga BC, Kumar S. Role of Bcl-2 family of proteins in malignancy. Hematol Oncol 2002;20:63-74.
9. Adams JM, Cory S. The Bcl-2 protein family: arbiters of cell survival. Science 1998;281:1322-1326
10. Cerroni L, Soyer HP, Kerl H. Bcl-2 protein expression in cutaneous malignant melanoma and benign melanocytic nevi. Am J Dermatopathol 1995;17:7-11.
11. Cotter FE, Waters J, Cunningham D. Human Bcl-2 antisense therapy for lymphomas. Biochim Biophys Acta 1999; 1489:97-106.
12. Banerjee D. Genasense (Genta Inc). Curr Opin Investig Drugs 2001;2:574-580
13. Dole M, Nunez G, Merchant AK, Maybaum J, Rode CK, Bloch CA, Castle VP. Bcl-2 inhibits chemotherapy-induced apoptosis in neuroblastoma. Cancer Res 1994;54:3253-3259
14. Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: a link between cancer genetics and chemotherapy. Cell 2002;108:153-164
15. Reed JC. Apoptosis-based therapies. Nat Rev Drug Discov 2002;1:111-121
16. Fisher DE. Apoptosis in cancer therapy: crossing the threshold. Cell 1994;78:539-542
17. Campos L, Rouault JP, Sabido O, Oriol P, Roubi N, Vasselon C, Archimbaud E, Magaud JP, Guyotat D. High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood 1993;81:3091-3096
18. McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LW, Hsieh JT, Tu SM, Campbell ML. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 1992;52:6940-6944
19. Hoffman AR, Hu JF. Directing DNA methylation to inhibit gene expression. Cell Mol Neurobiol 2006;26:425-438
20. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, Sutherland GR, Smith TD, Rauch C, Smith CA, Goodwin RG. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995;3: 673-682
21. Tock B, Zwiebel JA, Schoenfeldt M. Clinical trials referral resource. Current clinical trials of G3139. Oncology (Huntingt) 2003;17:1244-6,51-3,58.
22. Rudin CM, Salgia R, Wang X, Hodgson LD, Masters GA, Green M, Vokes EE. Randomized phase II study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103. J Clin Oncol 2008;26:870-876
23. Knox JJ, Chen XE, Feld R, Nematollahi M, Cheiken R, Pond G, Zwiebel JA, Gill S, Moore M. A phase I-II study of oblimersen sodium (G3139, Genasense) in combination with doxorubicin in advanced hepatocellular carcinoma (NCI # 5798). Invest New Drugs 2008;26:193-194
24. Parris GE. Why G3139 works poorly in cancer trials but might work well against HIV. Med Hypotheses 2007;69: 537-540
25. Wacheck V, Losert D, Gunsberg P, Vornlocher HP, Hadwiger P, Geick A, Pehamberger H, Muller M, Jansen B. Small interfering RNA targeting bcl-2 sensitizes malignant melanoma. Oligonucleotides 2003;13:393-400.
26. Lima RT, Martins LM, Guimaraes JE, Sambade C, Vasconcelos MH. Specific downregulation of bcl-2 and xIAP by RNAi enhances the effects of chemotherapeutic agents in MCF-7 human breast cancer cells. Cancer Gene Ther 2004; 11:309-316
27. Huang SL, Wu Y, Yu H, Zhang P, Zhang XQ, Ying L, Zhao HF. Inhibition of Bcl-2 expression by a novel tumor-specific RNA interference system increases chemosensitivity to 5-fluorouracil in Hela cells. Acta Pharmacol Sin 2006;27:242-248
28. Zhang H, Wang H, Zhang J, Qian G, Niu B, Fan X, Lu J, Hoffman AR, Hu JF, Ge S. Enhanced therapeutic efficacy by simultaneously targeting two genetic defects in tumors. Mol Ther 2009;17: 57-64.
29. Lim LP, Lau NC, Weinstein EG, Abdelhakim A, Yekta S, Rhoades MW, Burge CB, Bartel DP. The microRNAs of Caenorhabditis elegans. Genes Dev 2003;17: 991-1008.
30. Rodriguez A, Griffiths-Jones S, Ashurst JL, Bradley A. Identification of mammalian microRNA host genes and transcription units. Genome Res 2004;14:1902-1910
31. Ashkenazi A. Directing cancer cells to self-destruct with pro-132#apoptoticreceptor agonists. Nat Rev Drug Discov 2008;7:1001-1012
32. Nagane M, Huang HJ, Cavenee WK. The potential of TRAIL for cancer chemotherapy. Apoptosis 2001;6: 191-197
33. Abou El Hassan MA, Mastenbroek DC, Gerritsen WR, Giaccone G, Kruyt FA. Overexpression of Bcl2 abrogates chemo-and radiotherapy-induced sensitisation of NCI-H460 non-small-cell lung cancer cells to adenovirus-mediated expression of full-length TRAIL. Br J Cancer 2004;91: 171-177
34. Chawla-Sarkar M, Bae SI, Reu FJ, Jacobs BS, Lindner DJ, Borden EC. Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells toApo2L/TRAIL-induced apoptosis. Cell Death Differ 2004; 11:915-923
35. Lagos-Quintana M, Rauhut R, Yalcin A, Meyer J, Lendeckel W, Tuschl T. Identification of tissue-specific microRNAs from mouse. Curr Biol 2002;12:735-739
36. Hu JF, Vu TH, Hoffman AR. Genomic deletion of an imprint maintenance element abolishes imprinting of both insulin-like growth factor II and H19. J Biol Chem 1997;272:20715-20720
37. Hu JF, Vu TH, Hoffman AR. Promoter-specific modulation of insulin-like growth factor II genomic imprinting by inhibitors of DNA methylation. J Biol Chem 1996; 271:18253-18262
38. Chen HL, Li T, Qiu XW, Wu J, Ling JQ, Sun ZH, Wang W, Chen W, Hou A, Vu TH, Hoffman AR, Hu JF. Correction of aberrant imprinting of IGF2 in human tumors by nuclear transfer-induced epigenetic reprogramming. EMBO J 2006; 25:5329-5338
39. Eis PS, Tam W, Sun L, Chadburn A, Li Z, Gomez MF, Lund E, Dahlberg JE. Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proc Natl Acad Sci USA 2005;102:3627-3632
40. Cullen BR. Transcription and processing of human microRNA precursors. Mol Cell 2004;16:861-865
41. Chung KH, Hart CC, Al-Bassam S, Avery A, Taylor J, Patel PD, Vojtek AB, Turner DL. Polycistronic RNA polymerase II expression vectors for RNA interference based on BIC/miR-155. Nucleic Acids Res 2006;34:e53.
42. Martinez LA, Naguibneva I, Lehrmann H, Vervisch A, Tchenio T, Lozano G, Harel-Bellan A. Synthetic small inhibiting RNAs: efficient tools to inactivate oncogenic mutations and restore p53 pathways. Proc Natl Acad Sci USA 2002;99:14849-14854
43. Fesik SW. Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer 2005;5:876-885
44. Zhang Y, Zhang YF, Bryant J, Charles A, Boado RJ, Pardridge WM. Intravenous RNA interference gene therapy targeting the human epidermal growth factor receptor prolongs survival in intracranial brain cancer. Clin Cancer Res 2004;10: 3667-3677
45. Yekta S, Shih IH, Bartel DP. MicroRNA-directed cleavage of HOXB8 mRNA. Science 2004;304:594-596
46. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, Blackie C, Chang L, McMurtrey AE, Hebert A, DeForge L, Koumenis IL, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999;104:155-162
47. Ferreira CG, Huisman C, Giaccone G. Novel approaches to the treatment of non-small cell lung cancer. Crit Rev Oncol Hematol 2002;41:57-77. (Pubitemid 34055730)
48. Voelkel-Johnson C, King DL, Norris JS. Resistance of prostate cancer cells to soluble TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) can be overcome by doxorubicin or adenoviral delivery of full-length TRAIL. Cancer Gene Ther 2002;9: 164-172
49. Seol JY, Park KH, Hwang CI, Park WY, Yoo CG, Kim YW, Han SK, Shim YS, Lee CT. Adenovirus-TRAIL can overcome TRAIL resistance and induce a bystander effect. Cancer Gene Ther 2003;10: 540-548
50. Ou D, Wang X, Metzger DL, James RF, Pozzilli P, Plesner A, Korneluk RG, Verchere CB, Tingle AJ. Synergistic inhibition of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human pancreatic b cells by Bcl-2 and X-linked inhibitor of apoptosis. Hum Immunol 2005;66: 274-284
51. Zhang Y, Ma H, Zhang J, Liu S, Liu Y, Zheng D. AAV-mediated TRAIL gene expression driven by hTERT promoter suppressed human hepatocellular carcinoma growth in mice. Life Sci 2008; 82:1154-1161